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Summary
	 Background:	 Mucopolysaccharidoses	(MPS)	are	inherited	metabolic	disorders	caused	by	deficiencies	in	enzymes	
involved	in	degradation	of	glycosaminoglycans.	MPS	type	III	(Sanfilippo	disease)	is	clinically	charac-
terized	mainly	by	progressive	and	severe	behavioral	disturbances	and	cognitive	dysfunction.	Recent	
1-year	experimental	treatment	of	10	patients	with	a	genistein	(4’,	5,	7-trihydroxyisoflavone)-rich	ex-
tract	resulted	in	improvement	of	tested	parameters,	including	cognitive	and	behavioral	functions.
	Material/Methods:	 Eight	pediatric	patients	with	Sanfilippo	disease	were	enrolled	into	the	study.	The	modified	version	
of	the	Brief	Assessment	Examination	was	used	to	assess	cognitive	functions.	Moreover,	18	different	
parameters	concerning	changes	in	conditions	of	patients	were	assessed	by	their	parents.
	 Results:	 During	the	first	year	of	the	treatment,	an	improvement	of	cognitive	functions	in	7	patients	and	sta-
bilization	in	1	patient	were	assessed,	while	after	the	third	year	(2-year	follow-up)	further	improve-
ment	was	observed	in	2	patients,	stabilization	in	3	patients	and	some	deterioration	in	3	patients.	
Monitoring	of	general	and	behavioral	symptoms	revealed	improvement	in	all	patients	after	the	
first	year	of	the	treatment,	further	improvement	in	5	patients,	and	deterioration	in	3	patients	dur-
ing	the	next	2	years.
	 Conclusions:	 We	conclude	that	the	treatment	of	Sanfilippo	patients	with	a	genistein-rich	soy	isoflavone	extract	
(called	gene	expression-targeted	isoflavone	therapy	[GET	IT])	may	be	effective	in	either	inhibi-
tion	(in	some	patients)	or	slowing	down	(in	other	patients)	of	behavioral	and	cognitive	problems	
over	a	longer	period.	An	increased	dose	of	genistein	may	improve	the	efficacy	of	the	treatment.
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Background
Mucopolysaccharidoses	(MPS)	are	genetic	disorders	from	the	
group	of	lysosomal	storage	diseases	[1,2].	These	disorders	are	
caused	by	mutations	in	genes	coding	for	enzymes	involved	in	
degradation	of	glycosaminoglycans	(GAGs).	Storage	of	GAGs	
in	cells	of	patients	results	in	progressive	damage	to	the	af-
fected	tissues,	including	the	heart,	respiratory	system,	bones,	
joints	and,	in	most	MPS	types	and	subtypes,	the	central	ner-
vous	system	(CNS).	MPS	are	usually	fatal	diseases,	with	aver-
age	expected	life	span	of	1	or	2	decades,	although	patients	
with	milder	forms	can	survive	into	adulthood	[2].	There	are	
11	known	types	and	subtypes	of	MPS,	and	each	type	is	vari-
able	in	severity	of	particular	symptoms	[2].	Prediction	of	se-
verity	and	clinical	progression	of	MPS	is	difficult,	even	when	
biochemical	and	genetic	parameters	are	determined	[3],	but	
recent	studies	indicate	that	considering	2	or	more	parame-
ters	may	give	significantly	better	results	than	attempting	to	
make	conclusions	based	on	a	single	biomarker	[4].
MPS	type	III	(MPS	III,	called	also	Sanfilippo	disease)	is	a	
group	of	4	conditions	(MPS	IIIA,	B,	C	and	D),	revealing	sim-
ilar	clinical	symptoms	and	characterized	by	lysosomal	storage	
of	heparan	sulfate	(HS),	one	of	GAGs	[5].	Particular	subtypes	
are	classified	according	to	gene	coding	for	an	enzyme	in-
volved	in	degradation	of	HS	(heparan	N-sulfatase	in	MPS	IIIA,	
a-N-acetylglucosaminidase	in	MPS	IIIB,	acetyl-CoA:	a-glycosa-
minide	acetyltransferase	in	MPS	IIIC	and	N-acetylglucosamine	
6-sulfatase	in	MPS	IIID)	which	is		defective.
Although	other	MPS	types	are	characterized	by	severe	somat-
ic	symptoms	and	either	some	(sometimes	also	severe)	or	no	
neurological	and	behavioral	problems,	MPS	III	is	specifically	
associated	with	severe	learning	difficulties	and	behavioral	dis-
turbances,	accompanied	with	relatively	mild	somatic	involve-
ment.	In	most	affected	patients	the	progressive	nature	of	the	
disease	leads	to	death	in	the	second	(or	rarely	third)	decade	
of	life.	As	this	disorder	primarily	affects	the	brain	and	nervous	
system,	attempts	to	cure	patients	have	been	especially	diffi-
cult,	and	aside	from	experimental	treatments	(see	below),	the	
best	care	that	can	be	offered	is	palliative	or	symptomatic	[5].
Enzyme	replacement	therapy	(ERT),	based	on	an	intrave-
nous	infusion	of	an	active,	recombinant	form	of	a	deficient	
enzyme,	is	currently	the	only	officially	approved	treatment	
of	MPS,	and	is	used	in	clinical	practice	for	MPS	types	I,	II	
and	VI	[6].	Unfortunately,	neurological	symptoms	due	to	
HS	accumulation	in	CNS	cannot	be	managed	by	ERT,	due	
to	an	 inefficient	delivery	of	proteins,	 including	recombi-
nant	enzymes,	through	the	blood-brain	barrier.
Substrate	reduction	therapy	(SRT),	called	also	substrate	
deprivation	therapy	(SDT),	is	an	alternative	approach	for	
treatment	of	patients	with	lysosomal	storage	diseases	[7,8].	
This	therapy	is	based	on	the	action	of	small	molecules	that	
may,	directly	or	indirectly,	impair	synthesis	of	compounds	
that	cannot	be	efficiently	degraded	in	cells	of	patients.	Since	
such	small	molecules	may	likely	cross	the	blood-brain-bar-
rier,	it	is	hoped	that	they	could	be	used	to	manage	neuro-
logical	symptoms	of	these	diseases.
Previous	studies	with	rhodamine	B	([9-(2-carboxyphenyl)-
6-diethylamino-3-xanthenylidene]-diethylammonium	chlo-
ride)	and	genistein	(5,	7-dihydroxy-3-(4-hydroxyphenyl)	
-4H-1-benzopyran-4-1)	revealed	that	each	of	these	compounds	
can	reduce	the	efficiency	of	GAG	synthesis	in	cells	of	various	
MPS	types	[9,10].	Importantly,	these	studies	demonstrated	
not	only	a	lack	of	further	GAGs’	accumulation,	but	also	a	
reduction	in	lysosomal	storage	of	these	compounds.	In	fact,	
recently	reported	experiments	indicated	that	RNA	interfer-
ence-mediated	silencing	of	genes	coding	for	various	GAG	syn-
thetases	causes	a	decrease	in	the	amount	of	the	storage	ma-
terial	in	cell	lines	of	patients	with	Sanfilippo	disease	[11,12].	
Tests	on	animal	models	of	Sanfilippo	disease	demonstrat-
ed	efficacy	of	rhodamine	B	and	genistein	in vivo,	including	
behavior	of	affected	and	treated	mice	[9,13,14].	Although	
it	is	unlikely	that	rhodamine	B	can	be	used	in	clinical	prac-
tice	due	to	its	potential	toxicity	to	humans	[9],	genistein	is	
a	non-toxic	and	safe	compound	[15].	Moreover,	unlike	rho-
damine	B,	the	mechanism	of	genistein-mediated	inhibition	
of	GAG	synthesis	has	been	demonstrated.	This	isoflavone	
inhibits	phsophorylation	of	the	epidermal	growth	factor	re-
ceptor	(EGFR),	which	in	turn	causes	an	impairment	of	ex-
pression	of	genes	coding	for	enzymes	necessary	for	GAG	syn-
thesis	[8].	Hence,	this	special	kind	of	SRT	has	been	called	
‘gene	expression-targeted	 isoflavone	therapy’	(abbreviat-
ed	as	GET	IT),	and	an	open-label,	pilot	study	in	10	pediat-
ric	MPS	III	patients,	treated	with	a	genistein-rich	isoflavone	
extract	for	12	months,	was	performed	[15].	After	1	year	of	
treatment,	statistically	significant	improvement	in	all	mea-
sured	parameters	(urinary	GAG	excretion,	hair	morpholo-
gy	and	cognitive	functions)	was	demonstrated	[15].
Since	 longer-term	effects	of	GET	IT	for	MPS	III	are	not	
known,	we	performed	a	follow-up	study	with	genistein-treated	
MPS	III	patients.	Considering	learning	difficulties	and	behav-
ioral	disturbances	to	be	the	most	severe	clinical	problems	of	
Sanfilippo	disease,	we	focused	on	monitoring	cognitive	func-
tions	and	general	status	of	patients,	including	their	behavior.
Material and Methods
Patients
The	patients	were	diagnosed	 for	Sanfilippo	disease	(ei-
ther	MPS	IIIA,	McKusick’s	OMIM	no.	252900,	or	MPS	IIIB,	
McKusick’s	OMIM	no.	252920)	by	estimation	of	urinary	GAG	
levels	(highly	elevated	GAG	levels,	observed	in	hemi-quan-
titative	electrophoretic	analysis,	gave	a	preliminary	indica-
tion	for	MPS)	and	measurement	of	activities	of	particular	
lysosomal	hydrolases	in	leukocytes.	Deficiency	in	activity	of	
heparan	N-sulfatase	(control	value:	4.1±1.4	nmoles/mg	of	
protein/18h)	or	a-N-aceltyl	glucosaminidase	(control	value:	
90±34	nmoles/mg	of	protein/42	h)	was	considered	as	a	di-
agnosis	for	MPS	IIIA	or	MPS	IIIB,	respectively.	Mutations	in	
genes	coding	for	the	above-mentioned	enzymes	were	deter-
mined	for	5	patients,	and	1	mutation	was	determined	for	1	
patient.	Eight	patients	(6	with	MPS	IIIA	and	2	with	MPS	IIIB)	
were	enrolled	into	the	study.	All	patients	were	of	Caucasian	
origin;	2	males	and	6	females.	Among	the	8	patients,	5	(pa-
tients:	IIIA-2,	IIIA-4,	IIIA-5,	IIIB-2	and	IIIB-5)	were	previous-
ly	enrolled	into	the	pilot	study	[15].	Information	about	all	
patients	enrolled	into	this	study	is	summarized	in	Table	1.
Treatment
The	MPS	III	patients	characterized	in	Table	1	were	treated	
for	36	months	with	a	genistein-rich	soy	isoflavone	extract	
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(called	SE-2000),	provided	by	the	manufacturer	(Biofarm,	
Poznań,	Poland)	 in	 the	 form	of	 tablets	(product	name	
Soyfem).	The	extract	consisted	of	genistin	and	genistein	
(26.90%),	daidzin	and	daidzein	(13.37%),	glycitin	and	gly-
citein	(1.98%),	and	soy	proteins,	carbohydrates	and	lipids	
(remaining	amount).	This	extract	was	administered	orally	
(in	the	form	of	whole	tablets	or	tablets	crushed	into	powder)	
at	the	dose	corresponding	to	5	mg	of	genistin	and	genistein	
(genistin	is	a	glycan	that	can	be	converted	to	genistien	by	
either	acid	environment	or	intestinal	bacterial	flora)	per	1	
kg	of	body	weight	daily.	The	extract	was	administered	twice	
a	day,	with	equal	amounts	at	morning	and	evening.	Two	
types	of	evaluation	(the	modified	BAE	test	and	parents’	
questionnaire,	both	described	in	the	next	subsections)	were	
performed	at	baseline	and	after	12	and	36	months	of	treat-
ment.	The	monitoring	of	adverse	effects	was	based	on	re-
ports	of	parents,	who	were	appropriately	instructed	to	signal	
any	such	effects	immediately	(by	either	phone	or	email,	with	
confirmation	of	receipt	of	the	information),	and	who	pro-
vided	an	assessment	of	such	effects	in	writing	every	3	months	
(even	if	no	adverse	effects	were	observed).	This	experimen-
tal	treatment	was	approved	by	the	Independent	Bioethics	
Committee	of	 the	Medical	University	of	Gdańsk,	Poland	
(approval	no.	NKEBN/398/2005).	Parents	of	the	children	
involved	in	this	study	signed	the	informed	consent	form.
The modified BAE test
To	assess	cognitive	 functions	and	behavioral	changes,	a	
modified	version	of	the	Brief	Assessment	Examination	[15]	
was	used.	This	test	estimated	the	following	parameters:	(i)	
alertness/activity,	(ii)	obeying	commands,	(iii)	pointing	at	
objects,	(iv)	pointing	at	colors,	(v)	matching	shapes,	(vi)	
speech,	(vii)	auditory	digit	 span,	and	(viii)	mathematics.	
The	maximum	possible	score	was	52	points.	Details	of	this	
test	are	shown	in	the	Appendix.
MPS type Patient no.a Gender Age (years)b Weight (kg)b Mutation(s)c Residual enzyme activityd
IIIA IIIA-2 Female 5 18 R74C/ G90R 0.01
IIIA-4 Female 6 28 nd/nd 0.12
IIIA-5 Male 7 30 R74C / R74C 1.5
IIIA-6 Female 3 22 S66W / S66W 0.15
IIIA-7 Female 7 30 R74C / R74C 0.01
IIIA-8 Female 18 30 R74C / R74C 0.01
IIIB IIIB-2 Male 14 36 E120X/nd 3.0
IIIB-5 Female 9 43 nd/nd 0.01
Table 1. Patients’ characteristics.
a Numbers of patients correspond to those described previously (15). Patients IIIA-2, IIIA-4, IIIA-5, IIIB-2 and IIIB-5 were enrolled also in that study;
b the presented values were measured at baseline; c nd – not determined; d residual activities of enzymes deficient in MPS IIIA and MPS IIIB were 
measured in leukocytes, and were determined as heparan N-sulfatase (MPS IIIA) in nmoles/mg of protein/18 h (controls: 4.1±1.4) or as α-N-aceltyl 
glucosaminidase (MPS IIIB) in nmoles/mg of protein/42 h (controls: 90±34).
Patient
BAE scorea Questionnaires (general score)b
Baseline 1 year 3 years Baseline 1 year 3 years
IIIA-2 14 19 21 –1 +16 +19
IIIA-4 0 4 4 +4 +21 +5
IIIA-5 11 17 19 –10 +22 +23
IIIA-6 25 29 25 0 +13 +8
IIIA-7 38 38 38 –1 +8 +7
IIIA-8 2 4 2 –3 +14 +15
IIIB-2 33 36 32 –4 +6 +13
IIIB-5 27 32 32 –16 +26 +29
Table 2.  Assessment of cognitive functions of patients by using the modified BAE test, and estimation of a generalized score for estimation of 
general and behavioral symptoms in patients.
a For information about calculation of the BAE score, see Appendix; b General score was calculate by summing all answers given by parents to 
18 questions included in the questionnaire (for details see Table 3), giving following weights to particular types of answers: (–2) considerably 
deteriorated, (–1) somewhat deteriorated, (0) no changes, (+1) somewhat improved, (+2) considerably improved.
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Parents’ observations
Parents	of	patients	were	asked	to	evaluate	18	different	pa-
rameters	concerning	changes	in	conditions	of	their	children	
from	a	year	before	the	onset	of	the	treatment	to	the	start	of	
the	therapy,	from	the	onset	of	the	treatment	to	a	year	after	
the	start	of	the	therapy,	and	from	the	onset	of	the	treatment	
to	3	years	after	the	start	of	therapy.	Parents	were	instructed	
to	be	objective.	Some	parents	reported	they	depended	also	
on	the	opinion	of	other,	uninitiated,	people	(eg,	teachers).
results
Eight	patients	suffering	from	Sanfilippo	disease	(MPS	IIIA	
and	IIIB)	were	monitored	during	an	experimental	therapy	
consisting	of	a	genistein-rich	soy	isoflavone	extract	(Soyfem)	
at	the	dose	of	5	mg/kg/day	for	24	months.	Five	of	these	pa-
tients	were	enrolled	in	a	1-year	pilot	study	(patients	IIIA-
2,	IIIA-4,	IIIA-5,	IIIB-2,	IIIB-5),	described	previously	[15],	
and	the	treatment	(called	GET	IT)	was	continued	for	the	
next	2	years	(parents	of	these	patients	collaborated	with	re-
searchers	for	the	next	2	years	and	sent	back	their	question-
naires	on	time;	although	parents	of	 the	other	5	patients	
also	agreed	to	collaborate,	they	failed	to	return	completed	
questionnaires	on	time).	Three	patients	were	selected	after	
the	onset	of	the	previous	trial.	Urinary	GAG	levels	and	hair	
morphology	are	relatively	simple	assays	that	can	be	used	for	
monitoring	of	MPS	treatment;	however,	they	do	not	reflect	
the	behavioral	and	cognitive	status	of	examined	patients.	
Moreover,	a	statistically	significant	improvement	in	GAG	ex-
cretion	and	normalization	of	hair	morphology	were	report-
ed	after	1	year	of	GET	IT	[15];	hence,	one	would	not	expect	
further	improvement	in	these	parameters	during	the	next	
24	months.	Since	cognitive	and	behavioral	dysfunctions	are	
the	most	severe	symptoms	in	Sanfilippo	disease,	we	decid-
ed	to	monitor	cognitive	ability	and	behavior	of	patients	by	
using	a	specific	psychological	test	and	a	questionnaire	for	
patients’	parents,	as	described	previously	[15].
Parameter
Scores given to patients by parentsa
Patient no.
IIIA-2 IIIA-4 IIIA-5 IIIA-6 IIIA-7 IIIB-8 IIIB-2 IIIB-5
Speech performance 0/+1/0 0/+1/0 –1/0/0 0/+1/–1 –1/0/0 0/0/0 0/0/0 –1/+2/+2
Speech understanding 0/+1/0 0/+1/0 –1/+1/+1 0/+2/0 0/+1/+1 0/+1/+1 0/+1/+1 –1/+2/+1
Activity 0/+1/+1 0/+2/+2 –1/+2/+2 0/+2/+1 0/+1/0 –1/0/+1 0/0/+1 0/+1/0
General behavior 0/+1/+1 0/+2/0 –1/+2/+2 0/+1/+1 0/+1/+1 0/+1/+2 0/+1/+1 –1/+2/+2
Sleeping problems 0/+1/+1 0/+1/+2 –1/+2/+2 0/+1/+1 0/0/0 0/+2/+2 –1/+1/+1 –2/+2/+2
Pain 0/0/+1 0/0/0 0/0/0 0/0/+1 0/0/–1 +1/+2/+2 0/0/0 –2/+2/+2
Walking 0/+2/–1 0/+1/–2 0/+2/0 0/+2/+2 0/0/0 –1/0/0 –1/0/+1 –2/+1/0
Hand mobility 0/0/+1 0/+1/–1 –1/+2/+2 0/0/+2 0/0/0 0/0/+1 0/0/+1 0/+1/+2
Joint mobility 0/0/+1 0/+2/–1 –1/+2/0 0/0/+1 0/0/0 0/0/0 0/0/0 –1/+1/+2
Breathing problems (day) 0/+1/+2 +1/+2/0 0/0/0 0/–1/0 0/+2/0 0/0/0 0/0/0 0/0/+2
Breathing problems 
(night) 0/+1/+2 +1/+2/+1 0/+2/+2 0/–1/+1 0/+2/0 0/0/0 0/0/0 –1/+2/+2
Infections –1/+2/+2 +2/+2/+2 0/+1/+2 0/–1/0 0/0/+2 0/0/0 0/+2/+2 –1/+2/+2
Vision 0/0/0 0/0/0 0/0/+2 0/0/0 0/0/+1 0/0/0 –1/0/+2 0/0/0
Hearing 0/0/0 0/+2/0 0/0/+2 0/+2/–1 0/0/0 0/0/0 0/0/0 0/0/+2
Skin 0/+2/+2 0/+1/+1 0/0/0 0/0/0 0/0/+2 0/+2/+2 0/0/0 –1/+2/+2
Hair 0/+2/+2 0/+1/+1 –1/+2/+2 0/+2/–1 0/+1/+1 0/+2/+2 0/0/+1 –1/+2/+2
Dyspeptic symptoms 0/+1/+2 0/+1/+1 –1/+2/+2 0/+2/–1 0/0/0 –1/+2/+1 –1/0/0 –1/+2/+2
Stools 0/0/+2 0/–1/–1 –1/+2/+2 0/+1/+2 0/0/0 –1/+2/+1 0/+1/+2 –1/+2/+2
Tabele 3. Parents’ assessment of patients’ condition.
a The first number (before the first slash sign) is a score for the comparison of changes in a particular child from a year before the onset of the 
treatment to the start of the therapy, the number between slashes is a score for the comparison of changes in a particular child from the onset of 
the treatment to a year after the start of the therapy, and the number after the second slash is a score for the comparison of changes in a particular 
child from the onset of the treatment to 3 years after the start of the therapy. The following score scale was used: considerably deteriorated (–2), 
somewhat deteriorated (–1), no changes (0), somewhat improved (+1), considerably improved (+2).
Med Sci Monit, 2011; 17(4): CR196-202 Piotrowska E et al – Gene expression-targeted isoflavone therapy
CR199
CR
Electronic PDF security powered by ISL-science.com
Th
is
 c
op
y 
is
 fo
r 
pe
rs
on
al
 u
se
 o
nl
y 
- d
is
tr
ib
ut
io
n 
pr
oh
ib
it
ed
.  
   
Th
is
 c
op
y 
is
 fo
r 
pe
rs
on
al
 u
se
 o
nl
y 
- d
is
tr
ib
ut
io
n 
pr
oh
ib
it
ed
.  
   
Th
is
 c
op
y 
is
 fo
r 
pe
rs
on
al
 u
se
 o
nl
y 
- d
is
tr
ib
ut
io
n 
pr
oh
ib
it
ed
.  
   
Th
is
 c
op
y 
is
 fo
r 
pe
rs
on
al
 u
se
 o
nl
y 
- d
is
tr
ib
ut
io
n 
pr
oh
ib
it
ed
.  
   
Th
is
 c
op
y 
is
 fo
r 
pe
rs
on
al
 u
se
 o
nl
y 
- d
is
tr
ib
ut
io
n 
pr
oh
ib
it
ed
.  
   
Th
is
 c
op
y 
is
 fo
r 
pe
rs
on
al
 u
se
 o
nl
y 
- d
is
tr
ib
ut
io
n 
pr
oh
ib
it
ed
.  
   
Th
is
 c
op
y 
is
 fo
r 
pe
rs
on
al
 u
se
 o
nl
y 
- d
is
tr
ib
ut
io
n 
pr
oh
ib
it
ed
.  
   
Th
is
 c
op
y 
is
 fo
r 
pe
rs
on
al
 u
se
 o
nl
y 
- d
is
tr
ib
ut
io
n 
pr
oh
ib
it
ed
.  
   
Th
is
 c
op
y 
is
 fo
r 
pe
rs
on
al
 u
se
 o
nl
y 
- d
is
tr
ib
ut
io
n 
pr
oh
ib
it
ed
.  
   
Th
is
 c
op
y 
is
 fo
r 
pe
rs
on
al
 u
se
 o
nl
y 
- d
is
tr
ib
ut
io
n 
pr
oh
ib
it
ed
.  
   
Th
is
 c
op
y 
is
 fo
r 
pe
rs
on
al
 u
se
 o
nl
y 
- d
is
tr
ib
ut
io
n 
pr
oh
ib
it
ed
.  
   
Th
is
 c
op
y 
is
 fo
r 
pe
rs
on
al
 u
se
 o
nl
y 
- d
is
tr
ib
ut
io
n 
pr
oh
ib
it
ed
.  
   
Th
is
 c
op
y 
is
 fo
r 
pe
rs
on
al
 u
se
 o
nl
y 
- d
is
tr
ib
ut
io
n 
pr
oh
ib
it
ed
.  
   
Th
is
 c
op
y 
is
 fo
r 
pe
rs
on
al
 u
se
 o
nl
y 
- d
is
tr
ib
ut
io
n 
pr
oh
ib
it
ed
.  
   
Th
is
 c
op
y 
is
 fo
r 
pe
rs
on
al
 u
se
 o
nl
y 
- d
is
tr
ib
ut
io
n 
pr
oh
ib
it
ed
.  
   
Th
is
 c
op
y 
is
 fo
r 
pe
rs
on
al
 u
se
 o
nl
y 
- d
is
tr
ib
ut
io
n 
pr
oh
ib
it
ed
.  
   
Th
is
 c
op
y 
is
 fo
r 
pe
rs
on
al
 u
se
 o
nl
y 
- d
is
tr
ib
ut
io
n 
pr
oh
ib
it
ed
.  
   
Th
is
 c
op
y 
is
 fo
r 
pe
rs
on
al
 u
se
 o
nl
y 
- d
is
tr
ib
ut
io
n 
pr
oh
ib
it
ed
.  
   
Th
is
 c
op
y 
is
 fo
r 
pe
rs
on
al
 u
se
 o
nl
y 
- d
is
tr
ib
ut
io
n 
pr
oh
ib
it
ed
.  
   
Th
is
 c
op
y 
is
 fo
r 
pe
rs
on
al
 u
se
 o
nl
y 
- d
is
tr
ib
ut
io
n 
pr
oh
ib
it
ed
.  
   
PE
RS
ON
AL
 U
SE
ON
LY
No	adverse	effects	of	the	therapy	were	reported	during	this	
study.	This	corroborates	the	conclusion	that	GET	IT	is	a	safe	
treatment,	as	described	previously	[15].
To	assess	cognitive	 functions	of	 the	patients,	a	modified	
BAE	psychological	test	(see	Appendix	for	details)	was	per-
formed	at	baseline,	and	at	12	and	36	months	after	the	start	
of	treatment.	During	the	first	year	of	the	treatment,	an	im-
provement	in	the	score	in	7	patients	and	stabilization	in	1	
patient	(IIIA-7)	were	observed	(Table	2),	which	corrobo-
rates	previous	results	[15].	After	the	third	year	(2-year	fol-
low-up)	further	improvement	(relative	to	results	after	the	
first	year)	was	observed	in	2	patients	(IIIA-2,	IIIA-5),	stabi-
lization	was	observed	in	3	patients	(IIIA-4,	IIIA-7,	IIIB-5),	
and	deterioration	was	observed	in	3	patients	(IIIA-6,	IIIA-8,	
IIIB-2).	In	this	last-mentioned	group	of	patients,	the	scores	
after	36	months	of	treatment	were	equal	or	very	similar	to	
those	achieved	at	baseline	(Table	2).
To	estimate	the	efficacy	of	the	treatment,	patients’	parents	
were	asked	to	evaluate	18	different	parameters	concerning	
changes	in	conditions	of	their	children	from	a	year	before	
the	start	of	the	treatment	to	the	start	of	the	therapy,	from	
the	onset	of	the	treatment	to	a	year	after	the	start	of	the	
therapy,	and	from	the	start	of	the	treatment	to	3	years	af-
ter	the	start	of	the	therapy.	As	expected,	parents	reported	
deterioration	of	patients	in	many	parameters	in	the	peri-
od	from	1	year	before	the	treatment	to	the	start	of	the	tri-
al,	which	confirmed	that	the	children	were	in	the	clinical-
ly	progressive	stage	of	the	disease	(Table	3).
To	estimate	status	of	the	patients,	we	calculated	a	general	
score	for	each	patient	on	the	basis	of	answers	to	the	ques-
tionnaires.	This	general	score	was	calculated	by	summing	
all	the	answers	and	giving	the	following	weights	to	partic-
ular	types	of	answers:	(–2)	considerably	deteriorated,	(–1)	
somewhat	deteriorated,	(0)	no	changes,	(+1)	somewhat	im-
proved,	and	(+2)	considerably	improved.The	results	of	ques-
tionnaires	revealed	improvement	in	all	patients	after	the	first	
year	of	treatment,	further	improvement	in	5	patients	(IIIA-2,	
IIIA-5,	IIIA-8,	IIIB-2,	IIIB-5),	and	deterioration	in	3	patients	
(IIIA-4,	IIIA-6,	IIIA-7),	during	the	next	2	years	(Table	2).
discussion
After	unsuccessful	trials	with	bone	marrow	transplantation	
and	with	treatments	employing	small	molecules,	either	mi-
glustat	or	glucosamine,	to	our	knowledge,	this	pilot	study	on	
a	specific	substrate	deprivation	therapy,	called	GET	IT,	dem-
onstrates	the	first	treatment	of	patients	with	Sanfilippo	dis-
ease	that	demonstrates	a	statistically	significant	improvement	
in	biochemical	and	morphological	parameters,	as	well	as	im-
provement	in	clinical	status	of	patients	[1,15,16].	Since	GET	
IT	appeared	to	be	a	promising	treatment,	in	the	absence	of	
information	on	clinical	effects	of	longer	treatment,	a	follow-
up	of	treated	patients	was	necessary.	In	this	report	we	present	
a	2-year	follow-up	of	Sanfilippo	disease	patients	treated	with	a	
genistein-rich	soy	isoflavone	extract	(Soyfem)	at	the	dose	cor-
responding	to	the	amount	of	genistein	equal	to	5	mg/kg/day.
When	monitoring	cognitive	abilities	and	general	status	of	
the	patients	after	the	third	year	of	 the	treatment,	we	ob-
served	either	further	improvement/stabilization	of	the	pa-
tients,	or	their	slow	deterioration.	This	is	in	contrast	to	rapid	
deterioration	of	untreated	MPS	III	patients	presented	in	the	
literature	[5]	and	evident	from	questionnaire	responses	in	
this	report	(Table	3).	Interestingly,	such	a	picture	of	the	clin-
ical	manifestation	of	symptoms	in	treated	MPS	III	patients	
is	similar	to	that	observed	during	ERT	of	MPS	I,	although	
only	effects	on	somatic	tissues	could	be	considered	in	the	
latter	case.	Namely,	MPS	I	patients	treated	with	laronidase	
improve	relatively	rapidly	during	the	first	several	months	of	
the	treatment,	and	then	slow	improvement,	stabilization	or	
slow	deterioration	occurs	[6,17].	It	is	plausible	that	during	
the	first	period	of	both	ERT	and	GET	IT,	the	reversible	ef-
fects	of	diseases	are	corrected,	and	thereafter	it	is	only	pos-
sible	to	either	prevent	further	progression	or	to	slow	the	ir-
reversible	changes.
The	question	remains	whether	it	is	possible	to	make	GET	IT	
more	efficient.	The	main	mechanism	of	genistein-mediat-
ed	impairment	of	GAG	synthesis	is	inhibition	of	phosphor-
ylation	of	EGFR	[8].	Thus,	one	might	predict	that	when	us-
ing	higher	doses	of	genistein	it	should	be	possible	to	slow	
the	GAG	production	even	more	effectively.	The	dose	of	the	
SE-2000	extract	used	 in	both	the	previous	 trial	[15]	and	
this	study	corresponded	to	the	amount	of	genistein	equal	
to	5	mg/kg/day.	Since	it	was	recently	reported	that	a	dose	
as	high	as	160	mg/kg/day	is	safe	(with	no	adverse	effects)	
for	MPS	IIIB	mice	[14],	it	is	likely	that	significantly	(at	least	
200%)	higher	doses	than	that	used	in	this	study	may	be	safe	
for	humans.	Therefore,	there	is	great	need	for	a	clinical	tri-
al	evaluating	GET	IT	for	Sanfilippo	disease.
Oxidative	stress,	inflammation,	cytotoxicity	and	apoptosis	
may	be	involved	in	the	mechanism	of	neurodegeneration	
in	Sanfilippo	disease	[18–20].	Moreover,	accumulation	of	
hyperphosphorylated	tau	protein	(P-tau),	which	forms	ag-
gregates	characteristic	of	Alzheimer’s	disease,	has	been	de-
tected	in	brains	of	MPS	IIIB	mice	[21].	Thus,	it	is	intrigu-
ing	that	genistein	has	been	described	as	a	factor	attenuating	
oxidative	stress	in	the	brain	[22],	having	a	neuroprotective	
effect	against	beta	amyloid-induced	neurotoxicity	[23,24],	
inhibiting	apoptosis	in	primary	neuronal	cell	cultures	[25],	
preventing	Alzheimer’s	disease-associated	 inflammation	
[26],	and	revealing	a	general	neuroprotective	effect	[27].	
Genistein,	apart	from	its	action	as	an	indirect	inhibitor	of	
GAG	synthesis	[8],	may	also	be	beneficial	for	MPS	III	pa-
tients	due	to	its	neuroprotective	functions.	Although	some	
of	these	functions	were	observed	in vitro	at	genistein	con-
centrations	as	low	as	100	nM,	in	most	in vivo	studies	some	
effects	were	evident	only	at	10–15	mg/kg	[22–27].	These	
facts	strengthen	the	need	for	results	of	clinical	studies	in	
which	patients	with	Sanfilippo	disease	are	treated	with	ge-
nistein	at	doses	of	10–15	mg/kg/day	or	higher.
Results	of	recent	studies	on	animals	suggest	that	GET	IT	
may	be	effective	in	treatment	of	other	types	of	MPS	[28].	
Since	improvement	in	CNS	was	observed	in	genistein-treat-
ed	mice	with	MPS	II	[28],	an	X	chromosome-linked	disorder	
[2],	GET	IT	could	be	considered	as	a	potential	treatment	
for	MPS	II-associated	mental	retardation	[29].
conclusions
The	treatment	of	Sanfilippo	patients	with	a	genistein-rich	soy	
isoflavone	extract	(GET	IT),	at	the	dose	corresponding	to	5	
mg/kg/day,	may	be	effective	in	either	inhibition	(in	some	
Clinical Research Med Sci Monit, 2011; 17(4): CR196-202
CR200
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patients)	or	slowing	(in	other	patients)	of	the	cognitive	dysfunc-
tion,	behavioral	problems	and	general	deterioration	caused	by	
the	disease,	over	a	period	of	3	years.	An	increase	in	the	dose	of	
genistein	is	suggested	to	improve	the	efficacy	of	the	treatment.
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appendix
The	modified	Brief	Assessment	Examination	(for	the	orig-
inal	test	see	refs.	30	and	31)
A. The point scale
1. Activity
	 General	excitement	0	points
	 Short-term	goal	directed	behaviour	2	points
	 Short-term	goal	directed	activity	4	points
	 Repeated	goal	directed	activity	6	points
	 Full	adequate	activity	8	points
2. Fulfilling simple commands
	 None	fulfilled	0	points
	 1	fulfilled	3	points
	 2	fulfilled	5	points
3. Pointing at objects
	 None	pointed	0	points
	 1	pointed	3	points
	 2	pointed	5	points
4. Pointing at colours
	 None	pointed	0	points
	 1	pointed	3	points
	 2	pointed	5	points
5. Matching shapes
	 None	matched	0	points
	 1	matched	3	points
	 2	matched	5	points
6. Speech
	 Absent	0	points
	 Individual	echoic	words	2	points
	 Individual	words	4	points
	 Simple	sentences	6	points
	 Expanded	statements	8	points
7. Aural digit span
	 None	reproduced	0	points
	 1	reproduced	4	points
	 2	reproduced	6	points
	 3	reproduced	8	points
8. Counting
	 Does	not	count	0	points
	 Counts	to	5	4	points
	 Counts	to10	8	points
B. Description of the scale
1. Activity
General	excitement	–	kinetic	excitement,	no	goal-oriented	
activity,	lack	of	even	short-term	concentration	on	a	single	
stimulus.	Also	dynamic	lack	of	any	activity.
Short-term	goal	directed	behaviour	–	temporary	concentra-
tion,	e.g.	watching	somebody	or	something.
Short-term	goal	directed	activity	–	conscious,	purposeful	
manipulation	of	an	 item,	visual	examination,	 intentional	
attempts	to	socialize.
Repeated	goal	directed	activity	–	likewise,	repeated	or	long-
term	conduct.
Full	adequate	activity	–	goal	directed	activity	dominates	in	
child’s	behaviour.
2. Fulfilling simple commands
Commands	like	”give	mammy	the	toy”,	„put	the	book	on	
the	shelve”,	„put	the	ball	into	the	bag”	may	be	supported	
by	the	gesture	but	without	presentation.
3.	Pointing	at	objects
Pointing	as	a	response	to	a	verbal	request,	e.g.	„show	me,	
where	the	flower	is”,	etc.
4. Pointing at colours
Pointing	items	in	a	named	colour,	e.g.	show	the	blue	block	
(among	several	basic	colours:	red,	yellow,	blue,	green	or	white).
5. Matching shapes
Matching	the	shapes	in	a	big	puzzle	–	into	the	holes	in	a	
desk:			
6. Speech
Absent,	beside	no	goal-directed	vocalization,	babbling,	
prattling.
Individual	echoic	words:	any	attempts	to	direct	towards	any-
body	vocal	communication,	any	repeated	voice	reactions	to	
the	stimuli,	etc.
Individual	words:	can	be	mispronounced	or	„own	expres-
sions”	can	be	used	consistently.
7. Aural digit span
Repeating	by	heart	digits	in	a	line	of	two	or	three	elements	
(e.g.	7–4,	5–8–2).
8. Couning
Does	not	count,	has	no	idea	of	numbers
Counts	to	5:	counts	items	in	the	limit	of	five
Counts	to	10:	counts	items	in	the	limit	of	10.
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